| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
57,860,000 |
| Market
Cap: |
227.97(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.47 - $11.89 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aldeyra Therapeutics is a biotechnology company focused on discovering and developing therapies designed to treat immune-mediated diseases. Co.'s primary product candidate, reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. Co. has additional product candidates in development for autoimmune diseases and other immune-mediated disease, as well as for proliferative vitreoretinopathy (PVR) and other retinal diseases. Co. has rights to ADX-2191, a vitreous-compatible methotrexate formulation for intraocular injection, for the prevention of PVR, a retinal disease, and primary vitreoretinal lymphoma, a rare cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
682,265 |
682,265 |
682,265 |
2,150,494 |
| Total Buy Value |
$2,768,372 |
$2,768,372 |
$2,768,372 |
$11,311,413 |
| Total People Bought |
1 |
1 |
1 |
3 |
| Total Buy Transactions |
5 |
5 |
5 |
17 |
| Total Shares Sold |
250,945 |
250,945 |
3,007,444 |
3,007,444 |
| Total Sell Value |
$805,803 |
$805,803 |
$5,259,111 |
$5,259,111 |
| Total People Sold |
3 |
3 |
4 |
4 |
| Total Sell Transactions |
7 |
7 |
9 |
9 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Edelman Joseph |
10% Owner |
– – • |
2024-04-05 |
4 |
B |
$4.74 |
$178,755 |
I/I |
37,712 |
9,275,851 |
1.5 |
-17% |
|
| Edelman Joseph |
10% Owner |
– – • |
2024-04-04 |
4 |
B |
$4.67 |
$655,112 |
I/I |
140,281 |
9,238,139 |
1.5 |
-16% |
|
| Edelman Joseph |
10% Owner |
– – • |
2024-04-03 |
4 |
B |
$4.09 |
$1,267,274 |
I/I |
309,847 |
9,097,858 |
1.5 |
-5% |
|
| Edelman Joseph |
10% Owner |
– – • |
2024-04-02 |
4 |
B |
$3.44 |
$640,015 |
I/I |
186,051 |
8,788,011 |
1.5 |
11% |
|
| Edelman Joseph |
10% Owner |
– – • |
2024-04-01 |
4 |
B |
$3.25 |
$27,216 |
I/I |
8,374 |
8,601,960 |
1.5 |
20% |
|
| Machatha Stephen |
Chief Development Officer |
• – – |
2024-03-12 |
4/A |
S |
$3.16 |
$36,503 |
D/D |
(11,537) |
252,812 |
|
- |
|
| Brady Todd C |
President and CEO |
• • – |
2024-03-12 |
4 |
S |
$3.05 |
$260,238 |
D/D |
(85,324) |
1,471,298 |
|
-31% |
|
| Machatha Stephen |
Chief Development Officer |
• – – |
2024-03-12 |
4 |
S |
$3.16 |
$36,503 |
D/D |
(11,537) |
243,495 |
|
-31% |
|
| Greenberg Bruce |
See Remarks |
• – – |
2024-03-11 |
4/A |
S |
$3.41 |
$44,968 |
D/D |
(13,201) |
130,154 |
|
- |
|
| Brady Todd C |
President and CEO |
• • – |
2024-03-11 |
4 |
S |
$3.27 |
$320,521 |
D/D |
(97,914) |
1,556,622 |
|
-21% |
|
| Machatha Stephen |
Chief Development Officer |
• – – |
2024-03-11 |
4 |
S |
$3.41 |
$62,102 |
D/D |
(18,231) |
255,032 |
|
-21% |
|
| Greenberg Bruce |
See Remarks |
• – – |
2024-03-11 |
4 |
S |
$3.41 |
$44,968 |
D/D |
(13,201) |
120,699 |
|
-21% |
|
| Edelman Joseph |
10% Owner |
– – • |
2023-10-18 |
4 |
S |
$1.74 |
$533,308 |
I/I |
(306,499) |
8,593,586 |
|
-113% |
|
| Edelman Joseph |
10% Owner |
– – • |
2023-10-16 |
4 |
S |
$1.60 |
$3,920,000 |
I/I |
(2,450,000) |
8,900,085 |
|
-100% |
|
| Brady Todd C |
President and CEO |
• • – |
2023-09-07 |
4 |
D |
$7.22 |
$532,887 |
D/D |
(73,807) |
1,654,536 |
|
- |
|
| Brady Todd C |
President and CEO |
• • – |
2023-09-07 |
4 |
OE |
$0.55 |
$150,728 |
D/D |
273,058 |
1,728,343 |
|
- |
|
| Phillips Gary M |
|
– • – |
2023-09-07 |
4 |
OE |
$0.55 |
$3,001 |
D/D |
5,437 |
14,812 |
|
- |
|
| Walker Neal |
|
– • – |
2023-08-22 |
4 |
OE |
$0.55 |
$5,301 |
D/D |
9,604 |
15,854 |
|
- |
|
| Bronstein Ben |
Director |
– • – |
2023-06-27 |
4 |
OE |
$0.55 |
$5,301 |
D/D |
9,604 |
28,248 |
|
- |
|
| Brady Todd C |
President and CEO |
• • – |
2023-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
238,750 |
1,455,285 |
|
- |
|
| Edelman Joseph |
10% Owner |
– – • |
2022-08-10 |
4 |
B |
$7.85 |
$117,750 |
I/I |
15,000 |
11,350,085 |
1.5 |
-16% |
|
| Edelman Joseph |
10% Owner |
– – • |
2022-08-09 |
4 |
B |
$7.50 |
$750,000 |
I/I |
100,000 |
11,335,085 |
1.5 |
-18% |
|
| Edelman Joseph |
10% Owner |
– – • |
2022-08-08 |
4 |
B |
$7.24 |
$702,280 |
I/I |
97,000 |
11,235,085 |
1.5 |
-16% |
|
| Edelman Joseph |
10% Owner |
– – • |
2022-08-05 |
4 |
B |
$6.95 |
$979,950 |
I/I |
141,000 |
11,138,085 |
1.5 |
-9% |
|
| Edelman Joseph |
10% Owner |
– – • |
2022-08-04 |
4 |
B |
$6.17 |
$586,767 |
I/I |
95,100 |
10,997,085 |
1.5 |
-0% |
|
112 Records found
|
|
Page 1 of 5 |
|
|
